Retatrutide and Heart-Risk Biomarkers

On 17 August 2026, Diabetes, Obesity and Metabolism published a post hoc analysis of cardiovascular risk biomarkers from two completed Phase 2 trials of retatrutide, led by Giuseppe Ruotolo of Eli Lilly and Company with Naveed Sattar of the University of Glasgow and Stephen Nicholls of Monash University^[1]. Across adults with obesity, with and without type 2 diabetes, the reanalysis found reductions of up to 26.9% in non-HDL cholesterol, up to 24.2% in apolipoprotein B, and up to 54.8% in high-sensitivity C-reactive protein^[1]. These are lipid and inflammatory biomarker changes, not a count of heart attacks or strokes prevented.

What the analysis measured

The paper draws on two randomised, double-blind, placebo-controlled trials that had already reported their main weight and glucose results. Study 1 enrolled 281 adults with obesity or overweight and type 2 diabetes, who received weekly retatrutide at 0.5, 4, 8 or 12 mg, dulaglutide 1.5 mg, or placebo for 36 weeks; mean baseline body mass index was 35.4 kg/m2^[2]. Study 2 enrolled 338 adults with clinical obesity but no diabetes, who received weekly retatrutide at 1, 4, 8 or 12 mg or placebo for 48 weeks; mean baseline body mass index was 37.4 kg/m2^[3]. Fasting blood samples collected at baseline and during treatment were reanalysed for lipids, apolipoproteins, lipoprotein particle subclasses, and inflammatory markers, with statistical significance set at a false discovery rate-adjusted p value below 0.05^[1].

The lipoprotein and inflammation numbers

Non-HDL cholesterol fell up to 21.0% in the type 2 diabetes trial and up to 26.9% in the obesity-only trial. Apolipoprotein B, a marker that counts the atherogenic particles LDL, VLDL and other triglyceride-rich lipoproteins, fell 21.4% and 24.2% respectively. Total triglyceride-rich lipoprotein particles dropped 22.5% and 33.7%, and the largest triglyceride-rich particles, the ones most strongly linked to residual cardiovascular risk, fell 84.4% and 76.6%^[1]. Total LDL particle number fell 19.7% and 23.5%, while small dense LDL particles, a subclass associated with higher atherogenic potential, fell by a similar 32.6% and 32.3% in each trial^[1].

The inflammatory markers moved in the same direction but only reached statistical significance in the obesity-only trial. High-sensitivity C-reactive protein fell 54.8% and interleukin-6 fell 29.6% in Study 2; the same markers changed in Study 1 but did not clear the significance threshold^[1]. The paper concludes that retatrutide was associated with reductions in atherogenic lipoproteins and inflammatory biomarkers linked to cardiovascular disease risk in adults with obesity, regardless of diabetes status^[1].

What we do not yet know

This is a post hoc, exploratory analysis of trials that were designed and powered to measure body weight and glucose control, not cardiovascular events. Neither trial tracked heart attacks, strokes, or cardiovascular deaths, so nothing here quantifies whether fewer of those events occurred. A biomarker moving in a favourable direction is a plausible signal, not proof that the underlying disease process changed enough to prevent an event^[1]. The dedicated study built to answer that harder question is TRIUMPH-Outcomes, a Phase 3 trial of roughly 10,000 participants with atherosclerotic cardiovascular disease, chronic kidney disease, or both, with an estimated primary completion in February 2029^[4].

The contrast with semaglutide is instructive. SELECT, semaglutide's dedicated cardiovascular outcomes trial, enrolled 17,604 adults with overweight or obesity and established cardiovascular disease and directly counted events: a major cardiovascular event occurred in 6.5% of the semaglutide group against 8.0% on placebo, a result regulators and clinicians can treat as proven benefit in that population^[5]. Retatrutide has no equivalent completed trial. Favourable biomarker movement is the kind of evidence that comes before an outcomes trial, not instead of one.

Where this sits alongside retatrutide's other data

Both trials behind this analysis are already known from their primary publications. Study 2, the obesity trial, is the one reported by Jastreboff and colleagues in the New England Journal of Medicine in 2023, where the 12 mg dose produced a mean 24.2% body-weight reduction at 48 weeks^[3]. Study 1, the type 2 diabetes trial, is the one reported by Rosenstock and colleagues in the Lancet the same year, where the 12 mg escalation arm reduced HbA1c by about 2.0 percentage points at 36 weeks^[2]. This new paper does not add participants or new trial arms. It reanalyses stored blood samples from those same cohorts for a cardiovascular-relevant biomarker panel that the original publications did not report in this depth.

That distinction matters when reading the headline figures. The analysis reports percentage changes in biomarkers measured over 36 or 48 weeks, while the event outcomes that matter to patients are heart attacks, strokes, cardiovascular death, and heart-failure events. The paper does not report those outcomes^[1].

Why this matters

Retatrutide remains in clinical development. The registered Phase 3 retatrutide page explains that its primary outcomes include cardiovascular and kidney event composites. This biomarker analysis does not establish that retatrutide lowers cardiovascular risk. The event results from TRIUMPH-Outcomes are the evidence needed to answer that question^[4].

This article is for educational and journalistic purposes only and does not constitute medical advice. Retatrutide is investigational and is not an approved treatment. Always consult a qualified healthcare professional about cardiovascular or weight-management care.